Further research indicated that GLPs attenuated the mRNA levels of hypertrophic and fibrotic markers to inhibit cardiac hypertrophy through the PPARγ/PGC-1α pathway. The gene discussed is PPARGC1A; the disease is cardiac hypertrophy.